In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on ...

Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of ...

For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H1-antihistamines, ...

Remibrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria in two identical randomized ...

A new groundbreaking study revealed that Remibrutinib showed promising results in treating chronic spontaneous urticaria.A recent study published in the New England Journal of Medicine outlined the ...

Dr Adam Friedman recounts how AAD 2025 highlighted advancements in chronic spontaneous urticaria management, with discussion on new therapies and the role of diet.

Novartis (NOVN: VX) has reported new data showing that its investigational BTK inhibitor, remibrutinib, significantly ...

The advent of remibrtuinib, a Bruton's tyrosine kinase inhibitor, may encourage dermatologists to take care of chronic spontaenous urticaria patients, says a presenter at the 2025 meeting of the ...

Now, with a pair of phase 3 trials for oral BTK inhibitor remibrutinib meeting their objectives, the Swiss pharma group is on course to file for approval of the drug, potentially ending a decade ...

Remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor, showed efficacy and favorable safety in phase 2b trials. Data from phase 3 trials are needed. In the identical ...